Senator Ogilvie, an expert in biotechnology, bio-organic chemistry and genetic engineering has had many scientific accomplishments in his career including the development of the chemistry of the “Gene Machine”, an automated process for the manufacture of DNA. He is also the inventor of Ganciclovir, a drug used worldwide to fight infections that occur when one’s immune system is weakened.
We are truly appreciative for Senator Ogilvie’s commitment and dedication to helping to advance health research and science in Canada. We are most thankful Dr Ogilvie’s research breakthroughs that have improved the lives of Canadians, especially those with rare diseases.
He has been a true friend to our rare disease community and we will miss him dearly.
Pictured (L to R):
Durhane Wong-Rieger, President & CEO, CORD
Senator Kelvin Ogilvie
Maureen Smith, Secretary, CORD
November 17, 2017
Toronto & Webcast
ARE YOU READY? On January 1, 2018, Ontario will roll out OHIP+. The transition will apply to all kids and youths under 25, including those currently on private drug insurance and including all drugs, including those currently provided under EAP. The Canadian Organization for Rare Disorders has received many questions about issues that could affect a smooth transition. What if the child’s drug is not listed in ODP or EAP? What if the criteria between the current private plan and OHIP+ are different? What about the private support program? What if … what if …? CORD invites patient groups, clinicians, industry, insurers, and other stakeholders to join Vivian Leong, A/Director for OHIP+ to work through potential issues to ensure a SMOOTH transition on January 1st and beyond. Please join us for a F2F and Webcast working session on November 17, 2017 from 9:00 am – 11:30 am. Space in person is strictly limited to 30 persons but attendance by Webcast is virtually unlimited.